CAMP4 THERAPEUTICS CORPORATION
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CAMP | FDMT | PRQR | XFOR | RNA | TRDA | |
|---|---|---|---|---|---|---|
| Market cap | 229.68M | 718.17M | 228.61M | 279.59M | 140.44M | 214.15M |
| P/E (TTM) | — | — | — | 141.0 | — | — |
| Forward P/E | -4.5 | -3.2 | -3.5 | -3.7 | -1.0 | -1.8 |
| Price/book | -281.5 | 1.8 | 2.6 | 1.7 | 0.7 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +8.28% | +30.39% | −34.15% | −5.05% | −44.34% | −9.24% |
| Today | −2.92% | −2.48% | −0.61% | −3.09% | −2.26% | −3.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CAMP news ›Camp4 Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $15 price target. The firm believes Camp4’s $190M EV d... Camp4 Therapeutics initiated with an Outperform at Oppenheimer Oppenheimer initiated…
Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $6 from $6.50 and keeps a Buy rating on the shares fo... Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan Chardan analyst Keay…
Camp4 Therapeutics Corp Registered Shs Stock , CAMP
The latest Camp4 Therapeutics stock prices, stock quotes, news, and CAMP history to help you invest and trade smarter. Camp4 Therapeutics Corp Registered Shs Stock , CAMP Camp4 Therapeutics Stock Snapshot Camp4 Therapeutics News More News…
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA)…
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory ... CAMP4 Therapeutics to Host Virtual Analyst Day…
Piper Sandler Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on CAMP4 Therapeutics Corporation, with a price target of $15.00. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead…
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage ... CAMP4 to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 01, 2026…
Analyzing CAMP4 Therapeutics (NASDAQ:CAMP) and Genelux (NASDAQ:GNLX)
Posted by Sarita Garza on Sep 29th, 2026 CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
Chardan Capital Cuts CAMP4 Therapeutics (NASDAQ:CAMP) Price Target to $6.00
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) had its price objective lowered by research analysts at Chardan Capital from $6.50 to $6.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com7
-
themarketsdaily.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.